Elder Law Weekly

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Elder Law Weekly


We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Hannover Medical School

Combined RAS-blockade and statins may have additive effects on systemic CV risk markers

Scientists in Germany report, "Therapeutic strategies to prevent atherosclerotic plaque progression and achieve plaque stabilization involve 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA)-reductase inhibitors (statins) and renin-angiotensin system (RAS)-blockade, but studies investigating the potentially additive effects of a combined treatment strategy are rare."

C. Grothusen and colleagues of the Hannover Medical School wrote, "We hypothesized that the adjunction of atorvastatin with telmisartan...

• View Other Issues of Elder Law Weekly
  
• View Other NewsRx Publications